这是一篇来自已证抗体库的有关人类 AMACR的综述，是根据15篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合AMACR 抗体。
AMACR 同义词: AMACRD; CBAS4; P504S; RACE; alpha-methylacyl-CoA racemase; 2-methylacyl-CoA racemase

圣克鲁斯生物技术
小鼠 单克隆（2A10F3）
  • 免疫组化; 人类; 1:500; 图 2
圣克鲁斯生物技术 AMACR抗体（santa Cruz, sc-81710)被用于被用于免疫组化在人类样品上浓度为1:500 (图 2). Oncol Lett (2016) ncbi
小鼠 单克隆（2A10F3）
  • 免疫组化-石蜡切片; 人类; 图 2
圣克鲁斯生物技术 AMACR抗体（santa Cruz, sc-81710)被用于被用于免疫组化-石蜡切片在人类样品上 (图 2). PLoS ONE (2015) ncbi
赛默飞世尔
兔 单克隆（13H4）
  • 免疫组化-石蜡切片; 人类; 1:100; 图 1
赛默飞世尔 AMACR抗体（Thermo Scientific, 13H4)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 1). Turk J Med Sci (2015) ncbi
兔 单克隆（13H4）
  • 免疫组化-石蜡切片; 人类; 1:100; 图 2a
赛默飞世尔 AMACR抗体（Thermo Scientific, 13H4)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 2a). Acta Chir Belg (2013) ncbi
丹科医疗器械技术服务（上海）有限公司
兔 单克隆（13H4）
  • 免疫组化-石蜡切片; 人类; 1:300; 表 s18
丹科医疗器械技术服务（上海）有限公司 AMACR抗体（Dako, M3616)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:300 (表 s18). Science (2017) ncbi
兔 单克隆（13H4）
  • 免疫组化-石蜡切片; 人类; 1:200; 图 1d
丹科医疗器械技术服务（上海）有限公司 AMACR抗体（Dako, M3616)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:200 (图 1d). Oncol Lett (2016) ncbi
兔 单克隆（13H4）
  • 免疫组化-石蜡切片; 人类; 1:200; 图 st2
丹科医疗器械技术服务（上海）有限公司 AMACR抗体（Dako, 13H4)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:200 (图 st2). Oncotarget (2016) ncbi
兔 单克隆（13H4）
  • 免疫组化; 人类; 1:100
丹科医疗器械技术服务（上海）有限公司 AMACR抗体（Dako, 13H4)被用于被用于免疫组化在人类样品上浓度为1:100. Urol Oncol (2015) ncbi
兔 单克隆（13H4）
  • 免疫组化-石蜡切片; 人类; 1:100
丹科医疗器械技术服务（上海）有限公司 AMACR抗体（Dako, 13H4)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Mol Imaging (2015) ncbi
兔 单克隆（13H4）
  • 免疫组化-石蜡切片; 人类; 1:100
丹科医疗器械技术服务（上海）有限公司 AMACR抗体（Dako, M3616)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Virchows Arch (2014) ncbi
BioLogo
兔 单克隆（13H4）
  • immunohistochemistry - free floating section; 人类; 图 1
BioLogo AMACR抗体（Biologo, 13H4)被用于被用于immunohistochemistry - free floating section在人类样品上 (图 1). Prostate (2016) ncbi
兔 单克隆（13H4）
  • 免疫组化; 人类; 1:200
BioLogo AMACR抗体（Biologo, 13H4)被用于被用于免疫组化在人类样品上浓度为1:200. Virchows Arch (2011) ncbi
兔 单克隆（13H4）
  • 免疫组化-石蜡切片; 人类; 1:100
BioLogo AMACR抗体（BioLogo, 13H4)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Hum Pathol (2011) ncbi
兔 单克隆（13H4）
  • 免疫组化-石蜡切片; 人类; 1:200
BioLogo AMACR抗体（Biologo, 13H4)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:200. Virchows Arch (2008) ncbi
兔 单克隆（13H4）
  • 免疫组化-石蜡切片; 人类; 1:25
BioLogo AMACR抗体（Biologo, P504S)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:25. Pathology (2006) ncbi
文章列表
  1. Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357: pubmed 出版商
  2. Sui X, Hu Y, Zhang C, Pan H, Li D. Prostate cancer metastasis to the distal phalanx of the left hallux: The first confirmed case and literature review. Oncol Lett. 2016;12:1074-1078 pubmed
  3. Ji C, Zhou M, Gan W, Zheng J, Yan X, Guo H. Advanced prostatic ductal carcinoma in a patient with a long survival time following a total pelvis exenteration: A case report. Oncol Lett. 2016;11:1509-1511 pubmed
  4. Meller S, Meyer H, Bethan B, Dietrich D, Maldonado S, Lein M, et al. Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer. Oncotarget. 2016;7:1421-38 pubmed 出版商
  5. Bonkhoff H. Significance of prostate cancer missed on needle biopsy tools for retrieving missed cancer. Prostate. 2016;76:369-75 pubmed 出版商
  6. Tsutsumi Y, Nomiyama T, Kawanami T, Hamaguchi Y, Terawaki Y, Tanaka T, et al. Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth. PLoS ONE. 2015;10:e0139709 pubmed 出版商
  7. Duyar S, Yilmaz A, Demirag F, ErdoÄŸan Y, Yazici Ã, Karakaya J. The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma. Turk J Med Sci. 2015;45:607-14 pubmed
  8. Suryavanshi M, Mehta A, Jaipuria J, Sharma A, Rawal S, Seth N. Weaker ERG expression in patients with ERG-positive prostate cancer is associated with advanced disease and weaker androgen receptor expression: An Indian outlook. Urol Oncol. 2015;33:331.e9-15 pubmed 出版商
  9. Gibbs S, Genega E, Salemi J, Kianzad V, Goodwill H, Xie Y, et al. Near-infrared fluorescent digital pathology for the automation of disease diagnosis and biomarker assessment. Mol Imaging. 2015;14: pubmed 出版商
  10. Seipel A, Samaratunga H, Delahunt B, Wiklund F, Wiklund P, Lindberg J, et al. Immunohistochemical profile of ductal adenocarcinoma of the prostate. Virchows Arch. 2014;465:559-65 pubmed 出版商
  11. Erdogan Y, Demirag F, Duyar S, Yilmaz A, Yazici U, Aydogdu K. Clinical significance of the expression of alpha-methylacyl-CoA racemase in squamous cell carcinoma and adenocarcinoma of the lung. Acta Chir Belg. 2013;113:263-9 pubmed
  12. Noske A, Zimmermann A, Caduff R, Varga Z, Fink D, Moch H, et al. Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer. Virchows Arch. 2011;459:91-7 pubmed 出版商
  13. Hailemariam S, Vosbeck J, Cathomas G, Zlobec I, Mattarelli G, Eichenberger T, et al. Can molecular markers stratify the diagnostic value of high-grade prostatic intraepithelial neoplasia?. Hum Pathol. 2011;42:702-9 pubmed 出版商
  14. Gunia S, May M, Scholmann K, Störkel S, Hoschke B, Koch S, et al. Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer. Virchows Arch. 2008;453:165-70 pubmed 出版商
  15. Went P, Sauter G, Oberholzer M, Bubendorf L. Abundant expression of AMACR in many distinct tumour types. Pathology. 2006;38:426-32 pubmed